Literature DB >> 26890571

Relationship between uric acid levels and progressive supranuclear palsy.

David M Brody1, Irene Litvan1,2, Steve Warner, David E Riley3, Deborah A Hall4, Benzi M Kluger5, David R Shprecher6, Christopher R Cunningham2.   

Abstract

INTRODUCTION: The pathophysiology of both PD and PSP is characterized by a pro-oxidant state. Uric acid is an oxidative stress marker. High uric acid blood levels have been associated with a reduced risk of PD and a decreased rate of disease progression. We investigated whether a low serum concentration of uric acid is also associated with PSP.
METHODS: We measured serum uric acid concentrations in a subsample of the ENGENE PSP Cohort that included 75 cases and 75 frequency-matched-by-sex healthy controls (69 spouses, 6 in-laws) from four centers willing to participate (Case Western, Rush University, University of Utah, and University of Louisville). Case severity was characterized using the total PSP-Rating Scale, UPDRS, and Mattis Dementia Rating Scale. Unconditional logistic regression, Pearson's chi-squared test, and analysis of variance were used, as appropriate.
RESULTS: The mean uric acid level among cases (4.0 mg/dL) was not significantly lower than that of controls (4.1 mg/dL). When controlling for sex, there were no between-group statistical differences in uric acid levels. Uric acid levels were not correlated with disease severity.
CONCLUSIONS: The results of this study do not provide evidence of uric acid having a protective role in PSP, even if oxidative injury is important in the pathophysiology of this disorder. The lack of statistical significance suggests that there is no direct association between uric acid levels and PSP. However, a small inverse association cannot be excluded.
© 2016 Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  case-control study; epidemiology; progressive supranuclear palsy; uric acid

Mesh:

Substances:

Year:  2016        PMID: 26890571      PMCID: PMC5258200          DOI: 10.1002/mds.26535

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Urate and neuroprotection trials.

Authors:  Michael A Schwarzschild; Eric A Macklin; Alberto Ascherio
Journal:  Lancet Neurol       Date:  2014-08       Impact factor: 44.182

2.  Utility of TICS-M for the assessment of cognitive function in older adults.

Authors:  Celeste A de Jager; Marc M Budge; Robert Clarke
Journal:  Int J Geriatr Psychiatry       Date:  2003-04       Impact factor: 3.485

3.  Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy.

Authors:  L C Park; D S Albers; H Xu; J G Lindsay; M F Beal; G E Gibson
Journal:  J Neurosci Res       Date:  2001-12-01       Impact factor: 4.164

4.  Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.

Authors:  D S Albers; S J Augood; D M Martin; D G Standaert; J P Vonsattel; M F Beal
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

5.  Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Authors:  Michael A Schwarzschild; Kenneth Marek; Shirley Eberly; David Oakes; Ira Shoulson; Danna Jennings; John Seibyl; Alberto Ascherio
Journal:  Mov Disord       Date:  2011-04-29       Impact factor: 10.338

6.  Aging and oxidative stress in progressive supranuclear palsy.

Authors:  K Aoyama; K Matsubara; S Kobayashi
Journal:  Eur J Neurol       Date:  2006-01       Impact factor: 6.089

7.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.

Authors:  O L Lopez; I Litvan; K E Catt; R Stowe; W Klunk; D I Kaufer; J T Becker; S T DeKosky
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

8.  Urate as a predictor of the rate of clinical decline in Parkinson disease.

Authors:  Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild
Journal:  Arch Neurol       Date:  2009-12

9.  Plasma urate and risk of Parkinson's disease.

Authors:  M G Weisskopf; E O'Reilly; H Chen; M A Schwarzschild; A Ascherio
Journal:  Am J Epidemiol       Date:  2007-06-20       Impact factor: 4.897

Review 10.  Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates.

Authors:  Anna Martínez; Manuel Portero-Otin; Reinald Pamplona; Isidre Ferrer
Journal:  Brain Pathol       Date:  2009-08-06       Impact factor: 6.508

View more
  4 in total

1.  Assessment of serum uric acid as risk factor for tauopathies.

Authors:  Tommaso Schirinzi; Giulia Di Lazzaro; Vito Luigi Colona; Paola Imbriani; Mohammad Alwardat; Giulia Maria Sancesario; Alessandro Martorana; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

2.  Elevated Serum Uric Acid Increases the Risk of Ischemic Stroke Recurrence and Its Inflammatory Mechanism in Older Adults.

Authors:  Han-Yu Zhu; Shu-Zhen Zhao; Meng-Li Zhang; Yan Wang; Zhi-Ming Pan; Hao-Ran Cheng; Ke Zhao; Zhen Wang
Journal:  Front Aging Neurosci       Date:  2022-03-08       Impact factor: 5.750

3.  Evaluation of simple antioxidant blood parameters in patients with migraine.

Authors:  Zhenzhen Yang; Pengfei Xu; Chaofan Geng; Hongju Zhang
Journal:  Front Neurol       Date:  2022-07-26       Impact factor: 4.086

4.  Brain gray matter abnormalities in progressive supranuclear palsy revisited.

Authors:  PingLei Pan; Yi Liu; Yang Zhang; Hui Zhao; Xing Ye; Yun Xu
Journal:  Oncotarget       Date:  2017-09-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.